Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 plus Sorafenib in Advanced HCC
NCT00882869Phase 2Completed
- Sponsor
- Aegera Therapeutics
- Start
- Mar 2009
- Primary completion
- Mar 2011
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AEG35156 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Aegera Therapeutics. Primary endpoints: Recommended Dose of AEG35156 in Combination with Sorafenib at 12 months and Progression-Free Survival at 12 months. Started Mar 2009; status: completed.
02
Drugs
AEG35156
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00882869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882869.